A forum for researchers, students and applicants in the field of cyclodextrin technology
The authors hypothesized that integrating tumor-targeted topoisomerase I inhibitor delivery with optimized PARP inhibitor scheduling could enable effective combination therapy
According to clinicaltrials.gov, currently, there are 14 cyclodextrin-related clinical trials that in the status of i) Not yet recruiting, ii)
Cyclodextrin-containing polymer (CDP) (represented by blue in the scheme) conjugated to camptothecin (CPT) (represented by red) forms 30-40-nm diameter nanoparticles
